Global CAR-T Therapy in Haematological Malignancy Market Research Report 2024(Status and Outlook)
Report Overview
This report provides a deep insight into the global CAR-T Therapy in Haematological Malignancy market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global CAR-T Therapy in Haematological Malignancy Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the CAR-T Therapy in Haematological Malignancy market in any manner.
Global CAR-T Therapy in Haematological Malignancy Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Celgene (Juno Therapeutics)
Novartis
Gilead (Kite Pharma)
Pfizer
CARsgen Therapeutics
Autolus Therapeutics
Aurora BioPharma
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Collectis
Allogene Therapeutics
Celyad
Market Segmentation (by Type)
Allogeneic
Autologous
Market Segmentation (by Application)
Hospitals
Cancer Research Centers
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the CAR-T Therapy in Haematological Malignancy Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
This report provides a deep insight into the global CAR-T Therapy in Haematological Malignancy market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global CAR-T Therapy in Haematological Malignancy Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the CAR-T Therapy in Haematological Malignancy market in any manner.
Global CAR-T Therapy in Haematological Malignancy Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Celgene (Juno Therapeutics)
Novartis
Gilead (Kite Pharma)
Pfizer
CARsgen Therapeutics
Autolus Therapeutics
Aurora BioPharma
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Collectis
Allogene Therapeutics
Celyad
Market Segmentation (by Type)
Allogeneic
Autologous
Market Segmentation (by Application)
Hospitals
Cancer Research Centers
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the CAR-T Therapy in Haematological Malignancy Market
- Overview of the regional outlook of the CAR-T Therapy in Haematological Malignancy Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the CAR-T Therapy in Haematological Malignancy Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of CAR-T Therapy in Haematological Malignancy
1.2 Key Market Segments
1.2.1 CAR-T Therapy in Haematological Malignancy Segment by Type
1.2.2 CAR-T Therapy in Haematological Malignancy Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global CAR-T Therapy in Haematological Malignancy Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global CAR-T Therapy in Haematological Malignancy Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET COMPETITIVE LANDSCAPE
3.1 Global CAR-T Therapy in Haematological Malignancy Sales by Manufacturers (2019-2024)
3.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Manufacturers (2019-2024)
3.3 CAR-T Therapy in Haematological Malignancy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global CAR-T Therapy in Haematological Malignancy Average Price by Manufacturers (2019-2024)
3.5 Manufacturers CAR-T Therapy in Haematological Malignancy Sales Sites, Area Served, Product Type
3.6 CAR-T Therapy in Haematological Malignancy Market Competitive Situation and Trends
3.6.1 CAR-T Therapy in Haematological Malignancy Market Concentration Rate
3.6.2 Global 5 and 10 Largest CAR-T Therapy in Haematological Malignancy Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY INDUSTRY CHAIN ANALYSIS
4.1 CAR-T Therapy in Haematological Malignancy Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Type (2019-2024)
6.3 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2019-2024)
6.4 Global CAR-T Therapy in Haematological Malignancy Price by Type (2019-2024)
7 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global CAR-T Therapy in Haematological Malignancy Market Sales by Application (2019-2024)
7.3 Global CAR-T Therapy in Haematological Malignancy Market Size (M USD) by Application (2019-2024)
7.4 Global CAR-T Therapy in Haematological Malignancy Sales Growth Rate by Application (2019-2024)
8 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET SEGMENTATION BY REGION
8.1 Global CAR-T Therapy in Haematological Malignancy Sales by Region
8.1.1 Global CAR-T Therapy in Haematological Malignancy Sales by Region
8.1.2 Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Region
8.2 North America
8.2.1 North America CAR-T Therapy in Haematological Malignancy Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe CAR-T Therapy in Haematological Malignancy Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific CAR-T Therapy in Haematological Malignancy Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America CAR-T Therapy in Haematological Malignancy Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa CAR-T Therapy in Haematological Malignancy Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Celgene (Juno Therapeutics)
9.1.1 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Basic Information
9.1.2 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Overview
9.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Market Performance
9.1.4 Celgene (Juno Therapeutics) Business Overview
9.1.5 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy SWOT Analysis
9.1.6 Celgene (Juno Therapeutics) Recent Developments
9.2 Novartis
9.2.1 Novartis CAR-T Therapy in Haematological Malignancy Basic Information
9.2.2 Novartis CAR-T Therapy in Haematological Malignancy Product Overview
9.2.3 Novartis CAR-T Therapy in Haematological Malignancy Product Market Performance
9.2.4 Novartis Business Overview
9.2.5 Novartis CAR-T Therapy in Haematological Malignancy SWOT Analysis
9.2.6 Novartis Recent Developments
9.3 Gilead (Kite Pharma)
9.3.1 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Basic Information
9.3.2 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Overview
9.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Market Performance
9.3.4 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy SWOT Analysis
9.3.5 Gilead (Kite Pharma) Business Overview
9.3.6 Gilead (Kite Pharma) Recent Developments
9.4 Pfizer
9.4.1 Pfizer CAR-T Therapy in Haematological Malignancy Basic Information
9.4.2 Pfizer CAR-T Therapy in Haematological Malignancy Product Overview
9.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Product Market Performance
9.4.4 Pfizer Business Overview
9.4.5 Pfizer Recent Developments
9.5 CARsgen Therapeutics
9.5.1 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Basic Information
9.5.2 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Overview
9.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Market Performance
9.5.4 CARsgen Therapeutics Business Overview
9.5.5 CARsgen Therapeutics Recent Developments
9.6 Autolus Therapeutics
9.6.1 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Basic Information
9.6.2 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Overview
9.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Market Performance
9.6.4 Autolus Therapeutics Business Overview
9.6.5 Autolus Therapeutics Recent Developments
9.7 Aurora BioPharma
9.7.1 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Basic Information
9.7.2 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Overview
9.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Market Performance
9.7.4 Aurora BioPharma Business Overview
9.7.5 Aurora BioPharma Recent Developments
9.8 Sorrento Therapeutics
9.8.1 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Basic Information
9.8.2 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Overview
9.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Market Performance
9.8.4 Sorrento Therapeutics Business Overview
9.8.5 Sorrento Therapeutics Recent Developments
9.9 Mustang Bio
9.9.1 Mustang Bio CAR-T Therapy in Haematological Malignancy Basic Information
9.9.2 Mustang Bio CAR-T Therapy in Haematological Malignancy Product Overview
9.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Product Market Performance
9.9.4 Mustang Bio Business Overview
9.9.5 Mustang Bio Recent Developments
9.10 Bluebird Bio
9.10.1 Bluebird Bio CAR-T Therapy in Haematological Malignancy Basic Information
9.10.2 Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Overview
9.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Market Performance
9.10.4 Bluebird Bio Business Overview
9.10.5 Bluebird Bio Recent Developments
9.11 Collectis
9.11.1 Collectis CAR-T Therapy in Haematological Malignancy Basic Information
9.11.2 Collectis CAR-T Therapy in Haematological Malignancy Product Overview
9.11.3 Collectis CAR-T Therapy in Haematological Malignancy Product Market Performance
9.11.4 Collectis Business Overview
9.11.5 Collectis Recent Developments
9.12 Allogene Therapeutics
9.12.1 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Basic Information
9.12.2 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Overview
9.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Market Performance
9.12.4 Allogene Therapeutics Business Overview
9.12.5 Allogene Therapeutics Recent Developments
9.13 Celyad
9.13.1 Celyad CAR-T Therapy in Haematological Malignancy Basic Information
9.13.2 Celyad CAR-T Therapy in Haematological Malignancy Product Overview
9.13.3 Celyad CAR-T Therapy in Haematological Malignancy Product Market Performance
9.13.4 Celyad Business Overview
9.13.5 Celyad Recent Developments
10 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET FORECAST BY REGION
10.1 Global CAR-T Therapy in Haematological Malignancy Market Size Forecast
10.2 Global CAR-T Therapy in Haematological Malignancy Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country
10.2.3 Asia Pacific CAR-T Therapy in Haematological Malignancy Market Size Forecast by Region
10.2.4 South America CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of CAR-T Therapy in Haematological Malignancy by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global CAR-T Therapy in Haematological Malignancy Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of CAR-T Therapy in Haematological Malignancy by Type (2025-2030)
11.1.2 Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of CAR-T Therapy in Haematological Malignancy by Type (2025-2030)
11.2 Global CAR-T Therapy in Haematological Malignancy Market Forecast by Application (2025-2030)
11.2.1 Global CAR-T Therapy in Haematological Malignancy Sales (K Units) Forecast by Application
11.2.2 Global CAR-T Therapy in Haematological Malignancy Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of CAR-T Therapy in Haematological Malignancy
1.2 Key Market Segments
1.2.1 CAR-T Therapy in Haematological Malignancy Segment by Type
1.2.2 CAR-T Therapy in Haematological Malignancy Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global CAR-T Therapy in Haematological Malignancy Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global CAR-T Therapy in Haematological Malignancy Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET COMPETITIVE LANDSCAPE
3.1 Global CAR-T Therapy in Haematological Malignancy Sales by Manufacturers (2019-2024)
3.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Manufacturers (2019-2024)
3.3 CAR-T Therapy in Haematological Malignancy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global CAR-T Therapy in Haematological Malignancy Average Price by Manufacturers (2019-2024)
3.5 Manufacturers CAR-T Therapy in Haematological Malignancy Sales Sites, Area Served, Product Type
3.6 CAR-T Therapy in Haematological Malignancy Market Competitive Situation and Trends
3.6.1 CAR-T Therapy in Haematological Malignancy Market Concentration Rate
3.6.2 Global 5 and 10 Largest CAR-T Therapy in Haematological Malignancy Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY INDUSTRY CHAIN ANALYSIS
4.1 CAR-T Therapy in Haematological Malignancy Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Type (2019-2024)
6.3 Global CAR-T Therapy in Haematological Malignancy Market Size Market Share by Type (2019-2024)
6.4 Global CAR-T Therapy in Haematological Malignancy Price by Type (2019-2024)
7 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global CAR-T Therapy in Haematological Malignancy Market Sales by Application (2019-2024)
7.3 Global CAR-T Therapy in Haematological Malignancy Market Size (M USD) by Application (2019-2024)
7.4 Global CAR-T Therapy in Haematological Malignancy Sales Growth Rate by Application (2019-2024)
8 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET SEGMENTATION BY REGION
8.1 Global CAR-T Therapy in Haematological Malignancy Sales by Region
8.1.1 Global CAR-T Therapy in Haematological Malignancy Sales by Region
8.1.2 Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Region
8.2 North America
8.2.1 North America CAR-T Therapy in Haematological Malignancy Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe CAR-T Therapy in Haematological Malignancy Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific CAR-T Therapy in Haematological Malignancy Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America CAR-T Therapy in Haematological Malignancy Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa CAR-T Therapy in Haematological Malignancy Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Celgene (Juno Therapeutics)
9.1.1 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Basic Information
9.1.2 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Overview
9.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Market Performance
9.1.4 Celgene (Juno Therapeutics) Business Overview
9.1.5 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy SWOT Analysis
9.1.6 Celgene (Juno Therapeutics) Recent Developments
9.2 Novartis
9.2.1 Novartis CAR-T Therapy in Haematological Malignancy Basic Information
9.2.2 Novartis CAR-T Therapy in Haematological Malignancy Product Overview
9.2.3 Novartis CAR-T Therapy in Haematological Malignancy Product Market Performance
9.2.4 Novartis Business Overview
9.2.5 Novartis CAR-T Therapy in Haematological Malignancy SWOT Analysis
9.2.6 Novartis Recent Developments
9.3 Gilead (Kite Pharma)
9.3.1 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Basic Information
9.3.2 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Overview
9.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Market Performance
9.3.4 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy SWOT Analysis
9.3.5 Gilead (Kite Pharma) Business Overview
9.3.6 Gilead (Kite Pharma) Recent Developments
9.4 Pfizer
9.4.1 Pfizer CAR-T Therapy in Haematological Malignancy Basic Information
9.4.2 Pfizer CAR-T Therapy in Haematological Malignancy Product Overview
9.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Product Market Performance
9.4.4 Pfizer Business Overview
9.4.5 Pfizer Recent Developments
9.5 CARsgen Therapeutics
9.5.1 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Basic Information
9.5.2 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Overview
9.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Market Performance
9.5.4 CARsgen Therapeutics Business Overview
9.5.5 CARsgen Therapeutics Recent Developments
9.6 Autolus Therapeutics
9.6.1 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Basic Information
9.6.2 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Overview
9.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Market Performance
9.6.4 Autolus Therapeutics Business Overview
9.6.5 Autolus Therapeutics Recent Developments
9.7 Aurora BioPharma
9.7.1 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Basic Information
9.7.2 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Overview
9.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Market Performance
9.7.4 Aurora BioPharma Business Overview
9.7.5 Aurora BioPharma Recent Developments
9.8 Sorrento Therapeutics
9.8.1 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Basic Information
9.8.2 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Overview
9.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Market Performance
9.8.4 Sorrento Therapeutics Business Overview
9.8.5 Sorrento Therapeutics Recent Developments
9.9 Mustang Bio
9.9.1 Mustang Bio CAR-T Therapy in Haematological Malignancy Basic Information
9.9.2 Mustang Bio CAR-T Therapy in Haematological Malignancy Product Overview
9.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Product Market Performance
9.9.4 Mustang Bio Business Overview
9.9.5 Mustang Bio Recent Developments
9.10 Bluebird Bio
9.10.1 Bluebird Bio CAR-T Therapy in Haematological Malignancy Basic Information
9.10.2 Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Overview
9.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Market Performance
9.10.4 Bluebird Bio Business Overview
9.10.5 Bluebird Bio Recent Developments
9.11 Collectis
9.11.1 Collectis CAR-T Therapy in Haematological Malignancy Basic Information
9.11.2 Collectis CAR-T Therapy in Haematological Malignancy Product Overview
9.11.3 Collectis CAR-T Therapy in Haematological Malignancy Product Market Performance
9.11.4 Collectis Business Overview
9.11.5 Collectis Recent Developments
9.12 Allogene Therapeutics
9.12.1 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Basic Information
9.12.2 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Overview
9.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Market Performance
9.12.4 Allogene Therapeutics Business Overview
9.12.5 Allogene Therapeutics Recent Developments
9.13 Celyad
9.13.1 Celyad CAR-T Therapy in Haematological Malignancy Basic Information
9.13.2 Celyad CAR-T Therapy in Haematological Malignancy Product Overview
9.13.3 Celyad CAR-T Therapy in Haematological Malignancy Product Market Performance
9.13.4 Celyad Business Overview
9.13.5 Celyad Recent Developments
10 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY MARKET FORECAST BY REGION
10.1 Global CAR-T Therapy in Haematological Malignancy Market Size Forecast
10.2 Global CAR-T Therapy in Haematological Malignancy Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country
10.2.3 Asia Pacific CAR-T Therapy in Haematological Malignancy Market Size Forecast by Region
10.2.4 South America CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of CAR-T Therapy in Haematological Malignancy by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global CAR-T Therapy in Haematological Malignancy Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of CAR-T Therapy in Haematological Malignancy by Type (2025-2030)
11.1.2 Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of CAR-T Therapy in Haematological Malignancy by Type (2025-2030)
11.2 Global CAR-T Therapy in Haematological Malignancy Market Forecast by Application (2025-2030)
11.2.1 Global CAR-T Therapy in Haematological Malignancy Sales (K Units) Forecast by Application
11.2.2 Global CAR-T Therapy in Haematological Malignancy Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. CAR-T Therapy in Haematological Malignancy Market Size Comparison by Region (M USD)
Table 5. Global CAR-T Therapy in Haematological Malignancy Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Manufacturers (2019-2024)
Table 7. Global CAR-T Therapy in Haematological Malignancy Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR-T Therapy in Haematological Malignancy as of 2022)
Table 10. Global Market CAR-T Therapy in Haematological Malignancy Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers CAR-T Therapy in Haematological Malignancy Sales Sites and Area Served
Table 12. Manufacturers CAR-T Therapy in Haematological Malignancy Product Type
Table 13. Global CAR-T Therapy in Haematological Malignancy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of CAR-T Therapy in Haematological Malignancy
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. CAR-T Therapy in Haematological Malignancy Market Challenges
Table 22. Global CAR-T Therapy in Haematological Malignancy Sales by Type (K Units)
Table 23. Global CAR-T Therapy in Haematological Malignancy Market Size by Type (M USD)
Table 24. Global CAR-T Therapy in Haematological Malignancy Sales (K Units) by Type (2019-2024)
Table 25. Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Type (2019-2024)
Table 26. Global CAR-T Therapy in Haematological Malignancy Market Size (M USD) by Type (2019-2024)
Table 27. Global CAR-T Therapy in Haematological Malignancy Market Size Share by Type (2019-2024)
Table 28. Global CAR-T Therapy in Haematological Malignancy Price (USD/Unit) by Type (2019-2024)
Table 29. Global CAR-T Therapy in Haematological Malignancy Sales (K Units) by Application
Table 30. Global CAR-T Therapy in Haematological Malignancy Market Size by Application
Table 31. Global CAR-T Therapy in Haematological Malignancy Sales by Application (2019-2024) & (K Units)
Table 32. Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Application (2019-2024)
Table 33. Global CAR-T Therapy in Haematological Malignancy Sales by Application (2019-2024) & (M USD)
Table 34. Global CAR-T Therapy in Haematological Malignancy Market Share by Application (2019-2024)
Table 35. Global CAR-T Therapy in Haematological Malignancy Sales Growth Rate by Application (2019-2024)
Table 36. Global CAR-T Therapy in Haematological Malignancy Sales by Region (2019-2024) & (K Units)
Table 37. Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Region (2019-2024)
Table 38. North America CAR-T Therapy in Haematological Malignancy Sales by Country (2019-2024) & (K Units)
Table 39. Europe CAR-T Therapy in Haematological Malignancy Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific CAR-T Therapy in Haematological Malignancy Sales by Region (2019-2024) & (K Units)
Table 41. South America CAR-T Therapy in Haematological Malignancy Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa CAR-T Therapy in Haematological Malignancy Sales by Region (2019-2024) & (K Units)
Table 43. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Basic Information
Table 44. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Overview
Table 45. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Celgene (Juno Therapeutics) Business Overview
Table 47. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy SWOT Analysis
Table 48. Celgene (Juno Therapeutics) Recent Developments
Table 49. Novartis CAR-T Therapy in Haematological Malignancy Basic Information
Table 50. Novartis CAR-T Therapy in Haematological Malignancy Product Overview
Table 51. Novartis CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Novartis Business Overview
Table 53. Novartis CAR-T Therapy in Haematological Malignancy SWOT Analysis
Table 54. Novartis Recent Developments
Table 55. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Basic Information
Table 56. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Overview
Table 57. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy SWOT Analysis
Table 59. Gilead (Kite Pharma) Business Overview
Table 60. Gilead (Kite Pharma) Recent Developments
Table 61. Pfizer CAR-T Therapy in Haematological Malignancy Basic Information
Table 62. Pfizer CAR-T Therapy in Haematological Malignancy Product Overview
Table 63. Pfizer CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Pfizer Business Overview
Table 65. Pfizer Recent Developments
Table 66. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Basic Information
Table 67. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Overview
Table 68. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. CARsgen Therapeutics Business Overview
Table 70. CARsgen Therapeutics Recent Developments
Table 71. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Basic Information
Table 72. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Overview
Table 73. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Autolus Therapeutics Business Overview
Table 75. Autolus Therapeutics Recent Developments
Table 76. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Basic Information
Table 77. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Overview
Table 78. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Aurora BioPharma Business Overview
Table 80. Aurora BioPharma Recent Developments
Table 81. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Basic Information
Table 82. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Overview
Table 83. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Sorrento Therapeutics Business Overview
Table 85. Sorrento Therapeutics Recent Developments
Table 86. Mustang Bio CAR-T Therapy in Haematological Malignancy Basic Information
Table 87. Mustang Bio CAR-T Therapy in Haematological Malignancy Product Overview
Table 88. Mustang Bio CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Mustang Bio Business Overview
Table 90. Mustang Bio Recent Developments
Table 91. Bluebird Bio CAR-T Therapy in Haematological Malignancy Basic Information
Table 92. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Overview
Table 93. Bluebird Bio CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Bluebird Bio Business Overview
Table 95. Bluebird Bio Recent Developments
Table 96. Collectis CAR-T Therapy in Haematological Malignancy Basic Information
Table 97. Collectis CAR-T Therapy in Haematological Malignancy Product Overview
Table 98. Collectis CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Collectis Business Overview
Table 100. Collectis Recent Developments
Table 101. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Basic Information
Table 102. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Overview
Table 103. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Allogene Therapeutics Business Overview
Table 105. Allogene Therapeutics Recent Developments
Table 106. Celyad CAR-T Therapy in Haematological Malignancy Basic Information
Table 107. Celyad CAR-T Therapy in Haematological Malignancy Product Overview
Table 108. Celyad CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Celyad Business Overview
Table 110. Celyad Recent Developments
Table 111. Global CAR-T Therapy in Haematological Malignancy Sales Forecast by Region (2025-2030) & (K Units)
Table 112. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Region (2025-2030) & (M USD)
Table 113. North America CAR-T Therapy in Haematological Malignancy Sales Forecast by Country (2025-2030) & (K Units)
Table 114. North America CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country (2025-2030) & (M USD)
Table 115. Europe CAR-T Therapy in Haematological Malignancy Sales Forecast by Country (2025-2030) & (K Units)
Table 116. Europe CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country (2025-2030) & (M USD)
Table 117. Asia Pacific CAR-T Therapy in Haematological Malignancy Sales Forecast by Region (2025-2030) & (K Units)
Table 118. Asia Pacific CAR-T Therapy in Haematological Malignancy Market Size Forecast by Region (2025-2030) & (M USD)
Table 119. South America CAR-T Therapy in Haematological Malignancy Sales Forecast by Country (2025-2030) & (K Units)
Table 120. South America CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country (2025-2030) & (M USD)
Table 121. Middle East and Africa CAR-T Therapy in Haematological Malignancy Consumption Forecast by Country (2025-2030) & (Units)
Table 122. Middle East and Africa CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country (2025-2030) & (M USD)
Table 123. Global CAR-T Therapy in Haematological Malignancy Sales Forecast by Type (2025-2030) & (K Units)
Table 124. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type (2025-2030) & (M USD)
Table 125. Global CAR-T Therapy in Haematological Malignancy Price Forecast by Type (2025-2030) & (USD/Unit)
Table 126. Global CAR-T Therapy in Haematological Malignancy Sales (K Units) Forecast by Application (2025-2030)
Table 127. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. CAR-T Therapy in Haematological Malignancy Market Size Comparison by Region (M USD)
Table 5. Global CAR-T Therapy in Haematological Malignancy Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Manufacturers (2019-2024)
Table 7. Global CAR-T Therapy in Haematological Malignancy Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR-T Therapy in Haematological Malignancy as of 2022)
Table 10. Global Market CAR-T Therapy in Haematological Malignancy Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers CAR-T Therapy in Haematological Malignancy Sales Sites and Area Served
Table 12. Manufacturers CAR-T Therapy in Haematological Malignancy Product Type
Table 13. Global CAR-T Therapy in Haematological Malignancy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of CAR-T Therapy in Haematological Malignancy
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. CAR-T Therapy in Haematological Malignancy Market Challenges
Table 22. Global CAR-T Therapy in Haematological Malignancy Sales by Type (K Units)
Table 23. Global CAR-T Therapy in Haematological Malignancy Market Size by Type (M USD)
Table 24. Global CAR-T Therapy in Haematological Malignancy Sales (K Units) by Type (2019-2024)
Table 25. Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Type (2019-2024)
Table 26. Global CAR-T Therapy in Haematological Malignancy Market Size (M USD) by Type (2019-2024)
Table 27. Global CAR-T Therapy in Haematological Malignancy Market Size Share by Type (2019-2024)
Table 28. Global CAR-T Therapy in Haematological Malignancy Price (USD/Unit) by Type (2019-2024)
Table 29. Global CAR-T Therapy in Haematological Malignancy Sales (K Units) by Application
Table 30. Global CAR-T Therapy in Haematological Malignancy Market Size by Application
Table 31. Global CAR-T Therapy in Haematological Malignancy Sales by Application (2019-2024) & (K Units)
Table 32. Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Application (2019-2024)
Table 33. Global CAR-T Therapy in Haematological Malignancy Sales by Application (2019-2024) & (M USD)
Table 34. Global CAR-T Therapy in Haematological Malignancy Market Share by Application (2019-2024)
Table 35. Global CAR-T Therapy in Haematological Malignancy Sales Growth Rate by Application (2019-2024)
Table 36. Global CAR-T Therapy in Haematological Malignancy Sales by Region (2019-2024) & (K Units)
Table 37. Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Region (2019-2024)
Table 38. North America CAR-T Therapy in Haematological Malignancy Sales by Country (2019-2024) & (K Units)
Table 39. Europe CAR-T Therapy in Haematological Malignancy Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific CAR-T Therapy in Haematological Malignancy Sales by Region (2019-2024) & (K Units)
Table 41. South America CAR-T Therapy in Haematological Malignancy Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa CAR-T Therapy in Haematological Malignancy Sales by Region (2019-2024) & (K Units)
Table 43. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Basic Information
Table 44. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Overview
Table 45. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Celgene (Juno Therapeutics) Business Overview
Table 47. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy SWOT Analysis
Table 48. Celgene (Juno Therapeutics) Recent Developments
Table 49. Novartis CAR-T Therapy in Haematological Malignancy Basic Information
Table 50. Novartis CAR-T Therapy in Haematological Malignancy Product Overview
Table 51. Novartis CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Novartis Business Overview
Table 53. Novartis CAR-T Therapy in Haematological Malignancy SWOT Analysis
Table 54. Novartis Recent Developments
Table 55. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Basic Information
Table 56. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Overview
Table 57. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy SWOT Analysis
Table 59. Gilead (Kite Pharma) Business Overview
Table 60. Gilead (Kite Pharma) Recent Developments
Table 61. Pfizer CAR-T Therapy in Haematological Malignancy Basic Information
Table 62. Pfizer CAR-T Therapy in Haematological Malignancy Product Overview
Table 63. Pfizer CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Pfizer Business Overview
Table 65. Pfizer Recent Developments
Table 66. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Basic Information
Table 67. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Overview
Table 68. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. CARsgen Therapeutics Business Overview
Table 70. CARsgen Therapeutics Recent Developments
Table 71. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Basic Information
Table 72. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Overview
Table 73. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Autolus Therapeutics Business Overview
Table 75. Autolus Therapeutics Recent Developments
Table 76. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Basic Information
Table 77. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Overview
Table 78. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Aurora BioPharma Business Overview
Table 80. Aurora BioPharma Recent Developments
Table 81. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Basic Information
Table 82. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Overview
Table 83. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Sorrento Therapeutics Business Overview
Table 85. Sorrento Therapeutics Recent Developments
Table 86. Mustang Bio CAR-T Therapy in Haematological Malignancy Basic Information
Table 87. Mustang Bio CAR-T Therapy in Haematological Malignancy Product Overview
Table 88. Mustang Bio CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Mustang Bio Business Overview
Table 90. Mustang Bio Recent Developments
Table 91. Bluebird Bio CAR-T Therapy in Haematological Malignancy Basic Information
Table 92. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Overview
Table 93. Bluebird Bio CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Bluebird Bio Business Overview
Table 95. Bluebird Bio Recent Developments
Table 96. Collectis CAR-T Therapy in Haematological Malignancy Basic Information
Table 97. Collectis CAR-T Therapy in Haematological Malignancy Product Overview
Table 98. Collectis CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Collectis Business Overview
Table 100. Collectis Recent Developments
Table 101. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Basic Information
Table 102. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Overview
Table 103. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Allogene Therapeutics Business Overview
Table 105. Allogene Therapeutics Recent Developments
Table 106. Celyad CAR-T Therapy in Haematological Malignancy Basic Information
Table 107. Celyad CAR-T Therapy in Haematological Malignancy Product Overview
Table 108. Celyad CAR-T Therapy in Haematological Malignancy Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Celyad Business Overview
Table 110. Celyad Recent Developments
Table 111. Global CAR-T Therapy in Haematological Malignancy Sales Forecast by Region (2025-2030) & (K Units)
Table 112. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Region (2025-2030) & (M USD)
Table 113. North America CAR-T Therapy in Haematological Malignancy Sales Forecast by Country (2025-2030) & (K Units)
Table 114. North America CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country (2025-2030) & (M USD)
Table 115. Europe CAR-T Therapy in Haematological Malignancy Sales Forecast by Country (2025-2030) & (K Units)
Table 116. Europe CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country (2025-2030) & (M USD)
Table 117. Asia Pacific CAR-T Therapy in Haematological Malignancy Sales Forecast by Region (2025-2030) & (K Units)
Table 118. Asia Pacific CAR-T Therapy in Haematological Malignancy Market Size Forecast by Region (2025-2030) & (M USD)
Table 119. South America CAR-T Therapy in Haematological Malignancy Sales Forecast by Country (2025-2030) & (K Units)
Table 120. South America CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country (2025-2030) & (M USD)
Table 121. Middle East and Africa CAR-T Therapy in Haematological Malignancy Consumption Forecast by Country (2025-2030) & (Units)
Table 122. Middle East and Africa CAR-T Therapy in Haematological Malignancy Market Size Forecast by Country (2025-2030) & (M USD)
Table 123. Global CAR-T Therapy in Haematological Malignancy Sales Forecast by Type (2025-2030) & (K Units)
Table 124. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type (2025-2030) & (M USD)
Table 125. Global CAR-T Therapy in Haematological Malignancy Price Forecast by Type (2025-2030) & (USD/Unit)
Table 126. Global CAR-T Therapy in Haematological Malignancy Sales (K Units) Forecast by Application (2025-2030)
Table 127. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of CAR-T Therapy in Haematological Malignancy
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global CAR-T Therapy in Haematological Malignancy Market Size (M USD), 2019-2030
Figure 5. Global CAR-T Therapy in Haematological Malignancy Market Size (M USD) (2019-2030)
Figure 6. Global CAR-T Therapy in Haematological Malignancy Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. CAR-T Therapy in Haematological Malignancy Market Size by Country (M USD)
Figure 11. CAR-T Therapy in Haematological Malignancy Sales Share by Manufacturers in 2023
Figure 12. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Manufacturers in 2023
Figure 13. CAR-T Therapy in Haematological Malignancy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market CAR-T Therapy in Haematological Malignancy Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by CAR-T Therapy in Haematological Malignancy Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global CAR-T Therapy in Haematological Malignancy Market Share by Type
Figure 18. Sales Market Share of CAR-T Therapy in Haematological Malignancy by Type (2019-2024)
Figure 19. Sales Market Share of CAR-T Therapy in Haematological Malignancy by Type in 2023
Figure 20. Market Size Share of CAR-T Therapy in Haematological Malignancy by Type (2019-2024)
Figure 21. Market Size Market Share of CAR-T Therapy in Haematological Malignancy by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global CAR-T Therapy in Haematological Malignancy Market Share by Application
Figure 24. Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Application (2019-2024)
Figure 25. Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Application in 2023
Figure 26. Global CAR-T Therapy in Haematological Malignancy Market Share by Application (2019-2024)
Figure 27. Global CAR-T Therapy in Haematological Malignancy Market Share by Application in 2023
Figure 28. Global CAR-T Therapy in Haematological Malignancy Sales Growth Rate by Application (2019-2024)
Figure 29. Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Region (2019-2024)
Figure 30. North America CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America CAR-T Therapy in Haematological Malignancy Sales Market Share by Country in 2023
Figure 32. U.S. CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada CAR-T Therapy in Haematological Malignancy Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico CAR-T Therapy in Haematological Malignancy Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe CAR-T Therapy in Haematological Malignancy Sales Market Share by Country in 2023
Figure 37. Germany CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (K Units)
Figure 43. Asia Pacific CAR-T Therapy in Haematological Malignancy Sales Market Share by Region in 2023
Figure 44. China CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (K Units)
Figure 50. South America CAR-T Therapy in Haematological Malignancy Sales Market Share by Country in 2023
Figure 51. Brazil CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa CAR-T Therapy in Haematological Malignancy Sales Market Share by Region in 2023
Figure 56. Saudi Arabia CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global CAR-T Therapy in Haematological Malignancy Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global CAR-T Therapy in Haematological Malignancy Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global CAR-T Therapy in Haematological Malignancy Market Share Forecast by Type (2025-2030)
Figure 65. Global CAR-T Therapy in Haematological Malignancy Sales Forecast by Application (2025-2030)
Figure 66. Global CAR-T Therapy in Haematological Malignancy Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of CAR-T Therapy in Haematological Malignancy
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global CAR-T Therapy in Haematological Malignancy Market Size (M USD), 2019-2030
Figure 5. Global CAR-T Therapy in Haematological Malignancy Market Size (M USD) (2019-2030)
Figure 6. Global CAR-T Therapy in Haematological Malignancy Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. CAR-T Therapy in Haematological Malignancy Market Size by Country (M USD)
Figure 11. CAR-T Therapy in Haematological Malignancy Sales Share by Manufacturers in 2023
Figure 12. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Manufacturers in 2023
Figure 13. CAR-T Therapy in Haematological Malignancy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market CAR-T Therapy in Haematological Malignancy Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by CAR-T Therapy in Haematological Malignancy Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global CAR-T Therapy in Haematological Malignancy Market Share by Type
Figure 18. Sales Market Share of CAR-T Therapy in Haematological Malignancy by Type (2019-2024)
Figure 19. Sales Market Share of CAR-T Therapy in Haematological Malignancy by Type in 2023
Figure 20. Market Size Share of CAR-T Therapy in Haematological Malignancy by Type (2019-2024)
Figure 21. Market Size Market Share of CAR-T Therapy in Haematological Malignancy by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global CAR-T Therapy in Haematological Malignancy Market Share by Application
Figure 24. Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Application (2019-2024)
Figure 25. Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Application in 2023
Figure 26. Global CAR-T Therapy in Haematological Malignancy Market Share by Application (2019-2024)
Figure 27. Global CAR-T Therapy in Haematological Malignancy Market Share by Application in 2023
Figure 28. Global CAR-T Therapy in Haematological Malignancy Sales Growth Rate by Application (2019-2024)
Figure 29. Global CAR-T Therapy in Haematological Malignancy Sales Market Share by Region (2019-2024)
Figure 30. North America CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America CAR-T Therapy in Haematological Malignancy Sales Market Share by Country in 2023
Figure 32. U.S. CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada CAR-T Therapy in Haematological Malignancy Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico CAR-T Therapy in Haematological Malignancy Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe CAR-T Therapy in Haematological Malignancy Sales Market Share by Country in 2023
Figure 37. Germany CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (K Units)
Figure 43. Asia Pacific CAR-T Therapy in Haematological Malignancy Sales Market Share by Region in 2023
Figure 44. China CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (K Units)
Figure 50. South America CAR-T Therapy in Haematological Malignancy Sales Market Share by Country in 2023
Figure 51. Brazil CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa CAR-T Therapy in Haematological Malignancy Sales Market Share by Region in 2023
Figure 56. Saudi Arabia CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa CAR-T Therapy in Haematological Malignancy Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global CAR-T Therapy in Haematological Malignancy Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global CAR-T Therapy in Haematological Malignancy Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global CAR-T Therapy in Haematological Malignancy Market Share Forecast by Type (2025-2030)
Figure 65. Global CAR-T Therapy in Haematological Malignancy Sales Forecast by Application (2025-2030)
Figure 66. Global CAR-T Therapy in Haematological Malignancy Market Share Forecast by Application (2025-2030)
